Press release
Europe Alzheimer’s Drug Pipeline Analysis
The incidence of Alzheimer’s disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer’s disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure on the social and health-care systems of the region. There is an urgent need for developing curative or disease-modifying therapies to offset the upcoming Alzheimer’s disease epidemic.Download Report:
http://www.pnspharma.com/buy-report.php?reporttitle=Europe-Alzheimer-Drug-Pipeline-Analysis
“Europe Alzheimer’s Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Alzheimer disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Alzheimer drug market based upon development process.
Following parameters for each drug profile in development phase are covered in “Europe Alzheimer’s Drug Pipeline Analysis” research report:
• Drug Profile Overview
• Alternate Names for Drug
• Active Indication
• Phase of Development
• Mechanism of Action
• Brand Name
• Patent Information
• Country for Clinical Trial
• Owner / Originator/ Licensee/Collaborator
• Administrative Route
• Drug Class
• ATC Codes
Europe Alzheimer’s Disease Drug Pipeline by Clinical Phase:
• Research: 19
• Preclinical: 49
• Clinical: 1
• Phase-I: 25
• Phase-I/II: 2
• Phase-II: 26
• Phase-II/III: 2
• Phase-III: 5
• Preregistration: 2
• Marketed: 10
• Unknown: 1
For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com
Recent Publication
* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022
PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.
Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Europe Alzheimer’s Drug Pipeline Analysis here
News-ID: 603398 • Views: …
More Releases from PNS Pharma
Global Gene Therapy Market Opportunity By Clinical Trials Pipeline sales Kymriah …
"Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlight:
o Global Gene Therapy Market Opportunity: > US$ 8 Billion
o Global Gene Therapy Clinical Pipeline: > 1000 Therapies In Clinical Trials
o Commercially Available Gene Therapies: 11
o USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials
o Cancer Accounts For 50% of Global Gene Therapy Trials
Download Report: https://www.pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026
Over the years, gene therapy has been highly responsible for decreasing the mortality rate…
Global Orphan Drug Market Clinical Trials Pipeline Report Market Study 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
Global Rare Disease Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
Global Orphan Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…